A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with docetaxel for the treatment of patients with advanced breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Docetaxel

Criteria

Inclusion Criteria:

• Female patients with confirmed advanced breast cancer.

• Patients with HER-2 negative disease with documented disease progression after (neo)adjuvant treatment with an anthracycline-based chemotherapy regimen.

• Patients with adequate general well-being, kidney and liver function.

Exclusion Criteria:

• Patients that have any condition that could affect patients safety, interfere with trial results, or makes the patient inappropriate for inclusion into study.

• Patients who have had prior chemotherapy for advanced breast cancer.

• Patients of child-bearing potential who are unwilling to use contraception.